Upcoming HDSA Research Webinars
The Roche/Genentech GENERATION HD2 Study of Tominersen
Wednesday, February 8, 2023 at 12:00 PM (ET)
Roche and Genentech have launched the GENERATION HD2 study of the huntingtin-lowering drug tominersen. Join HDSA as Roche/Genentech representatives Lauren Boak, Lifecycle Leader in Neurosciences and Rare Diseases, and Dr. Peter McColgan, Clinical Science Leader, speak about the study and address community questions.
Novartis Discusses the VIBRANT-HD Trial
Wednesday, February 22, 2023 at 12:00 PM (ET)
Join us for an HDSA Research Webinar in which clinical leaders and Novartis representatives will talk about the VIBRANT-HD trial and the decision to stop development of branaplam in HD, and answer community questions. Speakers will include VIBRANT-HD clinical site investigator and chair of the trial Steering Committee Dr. Blair Leavitt, Director of Research and Consultant Neurologist at the UBC Centre for Huntington Disease; Medical lead for the branaplam program, Dr. Harry Ramos, Senior Clinical Development Medical Director at Novartis, and Clinical program head for the branaplam program, Dr. Beth Borowsky, Executive Director and Senior Global Program Clinical Head at Novartis.